Domperidone Overdose and Arrhythmia Risk
Yes, domperidone overdose can cause cardiac arrhythmias even in patients with a normal baseline QT interval, though the risk increases substantially with higher doses and is dose-dependent.
Mechanism and Risk Profile
Domperidone is a D2 dopamine receptor antagonist that blocks the rapidly activating delayed rectifier potassium current (IKr), leading to QT interval prolongation and potential ventricular arrhythmias, including torsades de pointes (TdP) 1, 2. The drug is specifically listed among antiemetics with "less frequent" but documented risk of QT prolongation and TdP 1.
Dose-Dependent Risk
The critical threshold appears to be doses >30 mg/day, where arrhythmia risk increases dramatically:
- Daily doses >30 mg are associated with an adjusted odds ratio of 11.4 (95% CI 1.99-65.2) for sudden cardiac death 3
- Current use of domperidone shows an overall increased risk with adjusted OR of 4.17 (95% CI 1.33-13.1) for sudden cardiac death 3
- Meta-analysis demonstrates significant cardiovascular event risk at doses >30 mg/day (OR: 3.14,95% CI 1.191-8.304) but not at doses ≤30 mg/day 4
Clinical Management in Overdose
In overdose situations, ECG monitoring of the QT interval should continue until drug levels have decreased and evidence of marked QT prolongation or associated arrhythmias is no longer present 5.
Key Monitoring Parameters
The 2025 AGA guidelines mandate specific monitoring even at therapeutic doses 6:
- Baseline ECG for QTc measurement
- Serum potassium and magnesium levels
- Continued monitoring while on treatment
High-Risk Features to Monitor
Patients are at immediate risk of torsades de pointes if they exhibit 5:
- Sudden bradycardia or long pauses (e.g., compensatory pauses after ventricular ectopy)
- Enhanced U waves
- T wave alternans
- Polymorphic ventricular premature beats, couplets
- Nonsustained polymorphic ventricular tachycardia
Risk Factors That Amplify Danger
Even with normal baseline QT, these factors substantially increase arrhythmia risk in overdose 5:
- Electrolyte abnormalities: Hypokalemia or hypomagnesemia (must be corrected immediately)
- Female sex: Women are at higher risk of acquired LQTS 7
- Older age: Increased susceptibility 7
- Bradycardia: Prolongs repolarization and predisposes to TdP 7
- Concomitant QT-prolonging drugs: Including macrolide antibiotics, fluoroquinolones, antipsychotics, other antiemetics 7, 2
- Underlying structural heart disease: Left ventricular hypertrophy, ischemia, or low ejection fraction 5
Treatment Approach for Overdose-Related Arrhythmias
If TdP or arrhythmic storm develops 7:
Immediate interventions:
- Cessation of domperidone
- Correction of electrolyte abnormalities (potassium >4 mM/L)
- Intravenous magnesium (even if serum magnesium is normal) - highly effective at suppressing TdP episodes
- Consider temporary transvenous pacing if recurrent after electrolyte correction
Contraindicated medications 7:
- Do NOT use amiodarone or procainamide - they further prolong QT interval and promote bradycardia
- These are specifically contraindicated for TdP arising from prolonged QT
Supportive measures:
- Continuous cardiac monitoring
- Maintain heart rate (avoid excessive bradycardia)
- Lidocaine may be considered 7
Important Clinical Context
The absolute risk remains relatively low but real: Population studies show domperidone is associated with increased risk of sudden cardiac death or ventricular arrhythmia compared to nonuse (adjusted OR: 1.69,95% CI 1.46-1.95) 8. However, in overdose situations with supratherapeutic concentrations, this risk is amplified beyond what therapeutic dose studies demonstrate.
Critical pitfall: The presence of a normal baseline QT interval does NOT eliminate risk in overdose, as the drug itself causes acquired QT prolongation in a dose-dependent manner. The QT interval will lengthen as drug concentrations rise, creating the substrate for arrhythmia even in previously normal hearts 7, 5.